71 results about "Anti metastasis" patented technology

Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL and its ligand GAS6.

The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others. Additional preferred embodiments of the subject invention relate to therapeutic compositions and methods treating or preventing rheumatoid arthritis, especially subcutaneous and intravenous formulations and dosage regimens using IL-6 antagonists according to the invention, as well as methods for preventing or treating GVHD or leukemia relapse in subjects receiving transplanted cells, tissue or organs, use thereof in the treatment or prevention of mucositis, and use thereof to potentiate the cytotoxic, apoptotic, and anti-metastatic or anti-invasive effects of chemotherapeutics and radiation on cancers, especially cancers that have developed a resistance to radiation or chemotherapy, such as an EGFR inhibitor.

The invention relates to methods for treating of tumor metastasis, methods for preventing, inhibiting, and predicting tumor recurrence and tumor metastasis, and methods of preventing cancer development for one at risk of developing cancer, for one diagnosed with a benign cancer, and/or for one diagnosed with malignant cancer. The invention also relates to methods of treating angiogenesis-dependent diseases and disorders. In addition, the invention provides: (1) a method for screening for tumor/cancer derived angiogenesis and metastasis factors; (2) a method for screening for compounds that inhibit angiogenesis and metastasis; (3) a method for screening for compounds that promote anti-angiogenesis and anti-metastasis activities; (4) a method for cancer prognosis evaluation; (5) a method for predicting the tissue specificity of a metastatic cancer; (6) a method for determining likelihood of metastasis; and (7) a method for cancer prognosis evaluation by the surveillance of metastasis development.

The present invention concerns particles comprising a chitin component, such as chitosan or a derivative thereof, associated with a polynucleotide encoding an interferon (IFN) molecule, 2-5′ oligoadenylate synthetase (2-5 AS), or a combination thereof. Preferably, the chitin component comprises chitosan or a derivative thereof. The particles of the invention are useful for delivery and expression of the interferon-encoding and/or 2-5 AS-encoding polynucleotide within a host in vitro or in vivo. The invention further concerns pharmaceutical compositions comprising particles of the invention and a pharmaceutically acceptable carrier, and a method for producing particles of the present invention. The present invention further pertains to a method of inducing apoptosis in a cancer cell, such as a lung cancer cell, by contacting a target cancer cell in vitro or in vivo with an effective amount of particles of the invention. In one embodiment, a therapeutically effective amount of particles are administered to target cancer cells within a patient in vivo, for treatment of cancer, such as lung cancer. The particles and therapeutic methods of the invention provide anti-metastatic and anti-cancer therapeutics for cancer patients, particularly lung cancer patients.

Provided is a composition that contains, as an active ingredient, an extract or polysaccharides separated from the leaves and/or stems of plants belonging to Panax genus, for an anticancer drug or its adjuvant, having an effect on the activity of hemotopoiesis enhancement, cancer metastasis inhibition, bone marrow defense, etc . . . , and a process for preparation of the extract from the leaves and/or stems of plants belonging to Panax genus.

Compositions and methods are provided for alleviating cancer in a mammal by administering a therapeutic dose of a pharmaceutical composition that inhibits activity of AXL, MER or Tyro3 protein activity, for example by competitive or non-competitive inhibition of the binding interaction between AXL, MER or Tyro3 and its ligand GAS6.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition capable of inhibiting tumor metastasis. Active ingredients of the traditional Chinese medicine composition include, by weight, 20-50 parts of radix astragali, 10-20 parts of rhizoma curcumae, 20-40 parts of radix pseudostellariae, 10-20 parts of poriacocos, 20-40 parts of rhizoma atractylodis macrocephalae, 20-40 parts of coix seed, 10-20 parts of fructus ligustri lucidi, 10-20 parts of fructus lycii, 10-20 parts of herba cistanche, 10-20 parts of fructus corni, 10-20 parts of radix polygonum multiflorum preparata, 15-30 parts of hedyotis diffusa and 15-30 parts of herba scutellariae barbatae. The invention further provides a preparation method and application of the traditional Chinese medicine composition. Main treatment rules of the composition are to tonify spleen and kidney, the composition can remarkably inhibit breast cancer cell MDA-MB-231 scratch formation, can inhibit cell migration and intrusion and has remarkable anti-metastasis effect; cytological experiments prove that the composition has efficacy of inhibiting tumor metastasis, and clinical experiments prove that the composition has remarkable effect on improving life quality of tumor patients.

The invention discloses a ruthenium complex containing a pyridine derivative as well as a preparation method and an application of the ruthenium complex. The structural formula of the complex is shown in the formula (I). The preparation method comprises the steps: grinding a reaction initiator trans-[RuCl4(SOR1R2)2][(SOR1R2)2H] into fine powder; stirring the initiator and ligand or performing ultrasonic oscillation in a reaction solvent, wherein the molar rate of the initiator to the ligand is 1:2-1:8 and the reaction temperature is 25-80 DEG C; or carrying out backflow; filtering precipitate formed after ultrasonic oscillation, and washing with acetone and diethyl ether; and drying by a silicon rubber dryer and keeping overnight. According to the preparation method of the ruthenium complex, the reaction time is short and the yield is high; and by using the prepared NA MI-A derivate, the anti-metastasis pesticide effect of Lewis experimental lung-cancer mice is significant, and the toxicity is low.

The invention relates to the field of biotechnology, especially to a detection kit of a novel target PNC for detection of tumor invasion and application thereof. The first detection antibody of the PNC detection kit for detecting tumor invasion is a PTB or CUG-BP1 antibody. The invention describes composition and application methods of a PNC immunohistochemical detection kit and a PNC immunofluorescence detection kit used for detecting tumor invasion. Furthermore, the invention also provides a method for screening a novel anti-metastasis compound and a Chinese herbal medicine monomer thereof; and the method for screening the novel anti-metastasis compound is also applicable to screening of small molecule compounds and Chinese herbal medicine monomers thereof. According to the invention, the proportion of PNC in a tissue sample of a cancer patient obtained through paracentesis is detected by using the PNC kits, so detection is simple and convenient, is easy to operate and has good stability; the proportion of PNC in tumor cells which have been affected by the compound is detected by using the PNC kits, computer programming and analysis are cooperatively used, so high throughput screening of a novel drug is realized.

The invention belongs to the field of cytobiology, and discloses a human lung cancer XL-2 highly metastatic cell line, called XL-2sci for short. The human lung cancer XL-2 highly metastatic cell line is characterized by being prepared through the step that conventional lung cancer cells XL-2 cells are subjected to animal in-vivo cyclic screening, and the conventional lung cancer cells XL-2 cells are preserved in the China Center for Type Culture Collection (CCTCC), and have the preservation number CCTCC NO C201282. The human lung cancer XL-2 highly metastatic cell line has the advantages that (1) through the repeated in-vivo screening, a human lung cancer XL-2 highly metastatic cell line model and a human lung cancer XL-2 highly metastatic cell line are successfully established, the metastasis rate is high, the metastasis is stable, the intuition is good, and the targeting is strong; (2) with the human lung cancer XL-2 highly metastatic cell line provided by the invention, an ideal model is provided for the prevention and cure research and anti-metastasis treatment on lung cancer.

The invention discloses a human lung adenocarcinoma cell LC-21, which belongs to the field of cytobiology. The human lung adenocarcinoma cell is characterized by being preserved in China Center for Type Culture Collection with an accession number of CCTCC No. C201287. The invention has the following advantages: (1) through repeated in-vitro screening, a human lung adenocarcinoma cell LC-21 cell line model and a human lung adenocarcinoma cell LC-21 cell line are successfully established, and the established model and cell line have a high metastasis rate, stable metastasis, good visualizability and strong targeting performance; and (2) the human lung adenocarcinoma cell LC-21 cell line provides an ideal model for prevention and cure research and anti-metastasis treatment of lung cancers.

The invention relates to a Chinese adenocarcinoma of lung cell strain Yang6 without transferring potential and an application and belongs to the biological zooblast system field. The Chinese adenocarcinoma of lung cell strain without transferring potential adopts pleural effusion of initial diagnosis later period adenocarcinoma of lung patients as cell primary culture, so that the Chinese adenocarcinoma of lung cell strain Yang6 without transferring potential is acquired, wherein a preservation number is CGMCC number (No.) 5404. The Chinese adenocarcinoma of lung cell strain Yang6 without transferring potential adherently grows on walls, possesses non-transitivity, and can be used as a people adenocarcinoma of lung comparative study cell model, wherein the shapes of cells are attractive and in a circle shape or a partial polygon shape, so that growth speed is low. The Chinese adenocarcinoma of lung cell strain without transferring potential has unique molecular biology character, heterogeneity, and polymorphism, and has a wide prospect in the application of disclosing a transferring mechanism of people adenocarcinoma of lung and selection of anti-metastasis drugs.